×

Tag: Vadim Gladyshev

ARDD Crowd
Once a year, Copenhagen becomes a Mecca for the longevity community. Hundreds of people flock to the picturesque Danish capital to attend the Aging Research and Drug Discovery Meeting (ARDD) for five full days of talks by geroscientists and biotech leaders, mingling and networking with like-minded longevity enthusiasts, and not-so-healthy late night-outs. ARDD is organized...
Trying to find a single cause of aging is like blinedfolded people trying to work out something is an elephant.
In the Proceedings of the National Academy of Science, Dr. Jesse Poganik and Prof. Vadim Gladyshev of Harvard Medical School have presented an opinion proposing a consensus understanding of aging. A problem of focus and funding The authors lament a lack of focus and funding in the field of gerontology, noting that a full 60%...
Full Biomarkers
The Biomarkers of Aging Consortium, an initiative uniting about 200 geroscientists around the goal to inform and guide the use of biomarkers of aging, has put out its first paper [1]. The need for biomarkers Since studies with lifespan as their endpoint can take a prohibitively long time, especially in humans, the importance of reliable...
A team led by renowned Harvard geroscientists David Sinclair and Vadim Gladyshev has reported successful chemically induced partial cellular reprogramming in vitro. The researchers have also developed a novel cellular rejuvenation assay [1]. Smaller than proteins Complete cellular reprogramming using the Yamanaka factors was first accomplished more than ten years ago [2]. Those four proteins,...
Vadim Gladyshev
Vadim Gladyshev is a Professor of Medicine at Brigham and Women's Hospital and Harvard Medical School, and he is one of the most prominent figures in geroscience today. We discussed various competing hypotheses on the nature of aging, the lack of the unified theory of aging and the need for one, and several fascinating papers...
Running Mice
A team of researchers, including Steve Horvath, Leonid Peshkin, and Vadim Gladyshev, has published a preprint on bioRxiv showing the effects of early administration of rapamycin over the lifespans of mice. Rapamycin before and after weaning In this placebo-controlled experiment, the researchers selected the UMHET3 strain of mice, as it is a crossbreed that does...